Mecasermin
| Clinical data | |
|---|---|
| Trade names | Increlex |
| AHFS/Drugs.com | Monograph |
| Pregnancy category |
|
| Routes of administration |
Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| Synonyms | FK-780; Recombinant human insulin-like growth factor-1; rhIGF-1; Somatomedin-1 |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C331H512N94O101S7 |
| Molar mass | 7648.67 g/mol |
  (what is this?)
|
|
Mecasermin (INN) (brand name Increlex), also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is recombinant form of human insulin-like growth factor 1 (IGF-I) which is used for the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).
A related drug is mecasermin rinfabate (trade name Iplex), which is a combination of rhIGF-1 and insulin-like growth factor binding protein-3 (IGFBP-3). IGFBP-3 serves to prolong the action of IGF-1 in the human body.
...
Wikipedia